Press Releases 2023 2022 2021 2020 2019 all June 28, 2019 Dyne Therapeutics Appoints Catherine Stehman-Breen to its Board of Directors June 17, 2019 Dyne Therapeutics Announces Support for END-DM1 Natural History Study of Patients with Myotonic Dystrophy Type 1 (DM1) June 13, 2019 Dyne Therapeutics Presents Nonhuman Primate Proof of Concept Data on FORCE™ Therapeutic Platform at International Myotonic Dystrophy Consortium Meeting (IDMC-12) April 3, 2019 Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases Pagination First page « Previous page ‹ Page 1 Page 2 Page 3 Current page 4 Displaying 61 - 64 of 64
